Search Results for: THERAPEUTIC FOCUS A New Patented
Articles
Orphan Drug Designation Granted to PTX-252 by FDA for the Treatment of Acute Myeloid Leukaemia January 17, 2024
Hyloris Pharmaceuticals SA recently announced the US FDA has granted Orphan Drug Designation to PTX-252 for the treatment of Acute...Lexaria Bioscience Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug Delivery Platform January 9, 2024
Lexaria Bioscience Corp. recently announced its placement in an editorial published by NetworkNewsWire (NNW), one of 60+ brands within the….
DELIVERY TECHNOLOGY - Topical NeuroDirect™ Ketamine in the Treatment of Neuropathic Pain Syndromes: Fibromyalgia, Neuropathy, Radiculopathy & Causalgia/Complex Regional Pain Syndrome October 2, 2023
Ronald Aung-Din, MD, and Chantelle Martin, MBChB, explain how targeting such chronic pain with a fast-acting, non-systemic, convenient, and easy-to-use at-home NeuroDirect ketamine cream could be of significant benefit in patients with CRPS as well as other neuropathic pain states, including chronic neck and back pain.
Ocean Biomedical’s mRNA-based Vaccine Candidate Generates Over 90% Killing of Malaria Parasites in Non-human Primates, Demonstrating Broad Potential to Address Global & Emerging US Malaria Challenges July 11, 2023
Ocean Biomedical, Inc. recently announced it is focusing its multi-pronged malaria program to address the chronic malaria crisis in sub-Saharan...Transgene & BioInvent Report Positive Phase 1a Data on Oncolytic Virus BT-001 in Solid Tumors May 25, 2023
Transgene and BioInvent International AB recently announce positive Phase 1a data on the oncolytic virus BT-001 for the treatment of solid tumors. Treatment with single agent BT-001 in 18 patients has now been….
Eisai Enters Joint Development Agreement With Blissbio for Antibody Drug Conjugate With Option Rights for Strategic Collaboration May 8, 2023
Eisai Co., Ltd. recently announced it has entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd., for BB-1701, an antibody-drug conjugate (ADC) with option rights for a….
FORMULATION FORUM - LIPIDSOL®: Liposomes - Chemistry, Properties & Applications of Lipid Nanoparticles May 1, 2023
Jim Huang, PhD, and Shaukat Ali, PhD, describe their LNP platform as well as the latest trends in LNPs as more and more novel therapeutic modalities discovered can’t be handled by traditional microemulsions or nanoemulsions.
SPECIAL FEATURE - Excipients: Their Future Could Lie in Generics April 3, 2023
Contributor Cindy H. Dubin highlights the innovative work being done by several leading companies and exemplifies the importance of excipients to the future of drug development.
Bhami Research Laboratory & Catalent Enter Licensing Agreement for Technology to Deliver High-Concentration Biologics Subcutaneously March 16, 2023
Bhami Research Laboratory (BRL) and Catalent recently announced a licensing agreement that will provide Catalent with access to BRL’s formulation...NeOnc Technologies Engages Anova Enterprises to Pursue Pediatric Brain Tumor Indication & FDA Fast-Track Status March 6, 2023
NeOnc Technologies Holdings, Inc. has recently expanded its engagement of Anova Enterprises to pursue a pediatric indication for NEO100, an...SPECIAL FEATURE - Solubility & Bioavailability: Difficult Beasts to Tame March 1, 2023
Contributor Cindy H. Dubin highlights the services many of these outsourced providers offer to enhance solubility and bioavailability and get their clients’ projects to market faster and cost effectively – while maintaining critical quality attributes.
DELIVERY TECHNOLOGY - NeuroDirect™ Ketamine: Novel, Non-Systemic Topical Therapy for PTSD & Associated Intractable Depression March 1, 2023
Ronald Aung-Din, MD, and Chantelle G. Martin, MBChB, present scientific data demonstrating how with NeuroDirect technology, the benefits of psychedelic compounds may be achieved without concern for their potential systemic effects.
Emerald Health Pharmaceuticals Receives Safety Review Committee Approval to Proceed to Final Cohorts of EHP-101 Phase 2a Systemic Sclerosis Trial January 11, 2023
Emerald Health Pharmaceuticals Inc. recently received a positive safety review following a pre-specified interim analysis by the Safety Review Committee...Transgene Receives Approval to Start a Phase 1 Trial of Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration January 6, 2023
Transgene recently announced it has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a Phase 1 clinical trial of TG6050, a novel oncolytic….
DRUG DISCOVERY - Leveraging the Human Gut as a Drug Discovery Tool November 30, 2022
Bridget Ann Martell MA, MD, says leveraging a patented technology that uses the human gut as a drug discovery tool has led to a new class of transformative precision therapeutics that disrupt inflammatory disease triggers — gut exclusive microbial metalloprotease inhibitors (GEMMI).
Xequel Bio Announces Positive Results From Phase 1b Study for Novel aCT1 Ophthalmic Solution July 14, 2022
Xequel Bio, Inc. recently announced positive results from its Phase 1b clinical trial with iNexin (aCT1 ophthalmic solution) for the...Sol-Gel Technologies & Galderma Announce FDA Approves First Topical Rosacea Treatment With Microencapsulated BPO April 25, 2022
Sol-Gel Technologies, Ltd. recently announced the Food and Drug Administration (FDA) approval of its drug product, EPSOLAY, a proprietary cream formulation of….
Geocann & Averix Bio Form Strategic Partnership to Supply Global Marketplace With Pharmaceutical API Phytocannabinoid Ingredients Formulated With Proven Delivery System April 13, 2022
Geocann recently announced a strategic partnership with Averix Bio that will bring US-produced API phytocannabinoid ingredients and clinically proven bioavailable...Exclusive License for Croda to Commercialize SSI’s CAF® Vaccine Adjuvants March 3, 2022
Croda International Plc, which uses smart science to improve lives, recently announces it has entered a strategic collaboration with Statens...SPECIAL FEATURE - Solubility & Bioavailability: Utilizing Enabling Technologies March 1, 2022
Contributor Cindy H. Dubin interviews several leading companies on how they are using innovative technologies, such as lipid nanoparticles to achieve a high drug loading, combining anti-solvent continuous crystallization with micro-mixing technology to control crystallization and reduce crystal size, and how a robotic capsule can improve bioavailability in the range of 47% to 78%.
